ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis)

Lynch syndrome, familial adenomatous polyposis, and Mut Y homolog (MYH)-associated polyposis are three major known types of inherited colorectal cancer, which accounts for up to 5% of all colon cancer cases. Lynch syndrome is most frequently caused by mutations in the mismatch repair genes MLH1, MSH2, MSH6, and PMS2 and is inherited in an autosomal dominant manner. Familial adenomatous polyposis is manifested as colonic polyposis caused by mutations in the APC gene and is also inherited in an autosomal dominant manner. Finally, MYH-associated polyposis is caused by mutations in the MUTYH gene and is inherited in an autosomal recessive manner but may or may not be associated with polyps. There are variants of both familial adenomatous polyposis (Gardner syndrome—with extracolonic features—and Turcot syndrome, which features medulloblastoma) and Lynch syndrome (Muir–Torre syndrome features sebaceous skin carcinomas, and Turcot syndrome features glioblastomas). Although a clinical diagnosis of familial adenomatous polyposis can be made using colonoscopy, genetic testing is needed to inform at-risk relatives. Because of the overlapping phenotypes between attenuated familial adenomatous polyposis, MYH-associated polyposis, and Lynch syndrome, genetic testing is needed to distinguish among these conditions. This distinction is important, especially for women with Lynch syndrome, who are at increased risk for gynecological cancers. Clinical testing for these genes has progressed rapidly in the past few years with advances in technologies and the lower cost of reagents, especially for sequencing. To assist clinical laboratories in developing and validating testing for this group of inherited colorectal cancers, the American College of Medical Genetics and Genomics has developed the following technical standards and guidelines. An algorithm for testing is also proposed.Genet Med 16 1, 101–116.

[1]  K. Felton,et al.  Constitutive deficiency in DNA mismatch repair , 2007, Clinical genetics.

[2]  R. Ward,et al.  The role of MYH and microsatellite instability in the development of sporadic colorectal cancer , 2006, British Journal of Cancer.

[3]  G. Plotz,et al.  Bethesda Guidelines: Relation to Microsatellite Instability and MLH1 Promoter Methylation in Patients with Colorectal Cancer , 2001, Annals of Internal Medicine.

[4]  J. Mecklin,et al.  The International Collaborative Group on HNPCC. , 1994, Anticancer research.

[5]  P. Radice,et al.  Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas , 2004, International journal of cancer.

[6]  K. Offit,et al.  Increased frequency of disease-causing MYH mutations in colon cancer families. , 2006, Carcinogenesis.

[7]  B. Zehnbauer,et al.  A high-throughput nonisotopic protein truncation test , 2003, Nature Biotechnology.

[8]  E. Hawk,et al.  The Future of Colon Cancer Prevention , 2001, Annals of the New York Academy of Sciences.

[9]  C. Amos,et al.  Loci for efficient detection of microsatellite instability in hereditary non-polyposis colorectal cancer. , 1999, Oncology reports.

[10]  R. Coates,et al.  Genetic Testing for Lynch Syndrome in Individuals Newly Diagnosed with Colorectal Cancer to Reduce Morbidity and Mortality from Colorectal Cancer in Their Relatives , 2011, PLoS currents.

[11]  C. Richards,et al.  Assay validation for identification of hereditary nonpolyposis colon cancer-causing mutations in mismatch repair genes MLH1, MSH2, and MSH6. , 2005, The Journal of molecular diagnostics : JMD.

[12]  E. Stoffel,et al.  Genetic testing for hereditary colorectal cancer: challenges in identifying, counseling, and managing high-risk patients. , 2010, Gastroenterology.

[13]  R. Fleischmann,et al.  Mutations of two P/WS homologues in hereditary nonpolyposis colon cancer , 1994, Nature.

[14]  M. Kloor,et al.  Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor , 2006, European Journal of Human Genetics.

[15]  P. Lynch.  The hMSH2 and hMLH1 genes in hereditary nonpolyposis colorectal cancer. , 2009, Surgical oncology clinics of North America.

[16]  P. Laird,et al.  Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. , 2011, The Journal of molecular diagnostics : JMD.

[17]  A. N. Bartley,et al.  Identification of Cancer Patients with Lynch Syndrome: Clinically Significant Discordances and Problems in Tissue-Based Mismatch Repair Testing , 2011, Cancer Prevention Research.

[18]  P. Propping,et al.  Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome , 2008, The Journal of pathology.

[19]  M. Choti,et al.  Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  A. Knudson.  Alfred Knudson and his two-hit hypothesis. (Interview by Ezzie Hutchinson). , 2001, The Lancet. Oncology.

[21]  Muin J. Khoury,et al.  Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting , 2011, Genetics in Medicine.

[22]  A. Viel,et al.  MLH1 and MSH2 constitutinal mutations in colorectal cancer families not meeting the standard criteria for hereditary nonpolyposis colorectal cancer , 1998, International journal of cancer.

[23]  R. Scott,et al.  MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer , 2010, Hereditary cancer in clinical practice.

[24]  A. Tenesa,et al.  Re: Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. , 2005, Journal of the National Cancer Institute.

[25]  G. Deng,et al.  Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. , 1999, Cancer research.

[26]  Monica R McClain,et al.  EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome , 2009, Genetics in Medicine.

[27]  W. Coyle,et al.  Colorectal Cancer Screening in Women with Endometrial Cancer: Are We Following the Guidelines? , 2012, Journal of Gastrointestinal Cancer.

[28]  S. Powell,et al.  Silencing-specific methylation and single nucleotide polymorphism of hMLH1 promoter in gastric carcinomas. , 2003, World journal of gastroenterology.

[29]  J. Mecklin,et al.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) , 1991, Diseases of the colon and rectum.

[30]  D. Gilchrist,et al.  Constitutive deficiency in DNA mismatch repair: is it time for Lynch III? , 2007, Clinical genetics.

[31]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[32]  R. Ward,et al.  Erasure of MLH1 methylation in spermatozoa—implications for epigenetic inheritance , 2007, Nature Genetics.

[33]  H. Lynch,et al.  EPCAM deletions, Lynch syndrome, and cancer risk. , 2011, The Lancet. Oncology.

[34]  S. Powell,et al.  Simultaneous detection of CpG methylation and single nucleotide polymorphism by denaturing high performance liquid chromatography. , 2002, Nucleic acids research.

[35]  E. Cook,et al.  Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. , 2012, JAMA.

[36]  G. Deng,et al.  Epigenetic changes (aberrant DNA methylation) in colorectal neoplasia. , 2007, Gut and liver.

[37]  A. Wagner,et al.  Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). , 2006, Gastroenterology.

[38]  Lora J. H. Bean,et al.  Targeted comparative genomic hybridization array for the detection of single- and multiexon gene deletions and duplications , 2009, Genetics in Medicine.

[39]  A. Duval,et al.  Quasimonomorphic Mononucleotide Repeats for High-Level Microsatellite Instability Analysis , 2004, Disease markers.

[40]  M. Bertagnolli,et al.  Molecular origins of cancer: Molecular basis of colorectal cancer. , 2009, The New England journal of medicine.

[41]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[42]  E. Pinto,et al.  Mutational Screening of the APC Gene in Chilean Families with Familial Adenomatous Polyposis: Nine Novel Truncating Mutations , 2007, Diseases of the colon and rectum.

[43]  K. Sotlar,et al.  Simplified detection of microsatellite instability in colorectal cancer without the need for corresponding germline DNA analysis , 2006, Journal of Clinical Pathology.

[44]  Aung Ko Win,et al.  Determining the frequency of de novo germline mutations in DNA mismatch repair genes , 2011, Journal of Medical Genetics.

[45]  Á. Carracedo,et al.  Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer , 2011, Gut.

[46]  J. Barrett,et al.  Testing guidelines for hereditary non-polyposis colorectal cancer , 2004, Nature Reviews Cancer.

[47]  B. Zehnbauer,et al.  A high-throughput nonisotopic protein truncation test , 2003, Nature Biotechnology.

[48]  R. Ward,et al.  Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer , 2009, Journal of Medical Genetics.

[49]  G. Deng,et al.  Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression , 2001, Oncogene.

[50]  W. Foulkes,et al.  A missense mutation in both hMSH2 andAPC in an Ashkenazi Jewish HNPCC kindred: implications for clinical screening , 1999, Journal of medical genetics.

[51]  Ira M. Lubin,et al.  Effective communication of molecular genetic test results to primary care providers , 2012, Genetics in Medicine.

[52]  D. Franchimont,et al.  The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP). , 2011, Acta gastro-enterologica Belgica.

[53]  A. Biggeri,et al.  Mutations of the APC Gene in Human Sporadic Colorectal Cancers , 2002, Scandinavian journal of gastroenterology.

[54]  Soma Das,et al.  Technical Standards and Guidelines: Molecular Genetic Testing for Ultra-Rare Disorders , 2005, Genetics in Medicine.

[55]  Y. Katayama,et al.  Promoter Hypermethylation of Mismatch Repair Gene hMLH1 Predicts the Clinical Response of Malignant Astrocytomas to Nitrosourea , 2005, Clinical Cancer Research.

[56]  E. Friedman,et al.  The I1307K APC polymorphism: prevalence in non-Ashkenazi Jews and evidence for a founder effect. , 2001, Genetic testing.

[57]  N. Lindor,et al.  Lynch syndrome and MYH-associated polyposis: review and testing strategy. , 2011, Journal of clinical gastroenterology.

[58]  J. Stockman,et al.  Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer: A Cost-Effectiveness Analysis , 2013 .

[59]  C. Sutter,et al.  Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue , 2004, Human mutation.

[60]  L. Lipton,et al.  Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. , 2003, The New England journal of medicine.

[61]  Joanne P Young,et al.  A perspective on bi-allelic MUTYH mutations in patients with hyperplastic polyposis syndrome. , 2009, Gastroenterology.

[62]  M. Urioste,et al.  Detection of APC gene deletions using quantitative multiplex PCR of short fluorescent fragments. , 2008, Clinical chemistry.

[63]  Julio Cesar Sampaio P. Leite,et al.  Is prophylactic colectomy indicated in patients with MYH‐associated polyposis? , 2005, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[64]  Bhramar Mukherjee,et al.  Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. , 2009, Gastroenterology.

[65]  L. Lipton,et al.  Proportion and phenotype of MYH-associated colorectal neoplasia in a population-based series of Finnish colorectal cancer patients. , 2003, The American journal of pathology.

[66]  Kenneth Offit,et al.  Systematic immunohistochemistry screening for Lynch syndrome in early age-of-onset colorectal cancer patients undergoing surgical resection. , 2012, Journal of the American College of Surgeons.

[67]  H. Vasen.  Review article: the Lynch syndrome (hereditary nonpolyposis colorectal cancer) * , 2007, Alimentary pharmacology & therapeutics.

[68]  A. Duval,et al.  Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. , 2002, Gastroenterology.

[69]  U. Ladabaum,et al.  Preferences for Genetic Testing to Identify Hereditary Colorectal Cancer: Perspectives of High-Risk Patients, Community Members, and Clinicians , 2011, Journal of Cancer Education.

[70]  A. Brehm,et al.  Germline MUTYH (MYH) mutations in Portuguese individuals with multiple colorectal adenomas , 2004, Human mutation.

[71]  M. Arends,et al.  DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome , 2010, Histopathology.

[72]  D. Bonthron,et al.  Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. , 2004, American journal of human genetics.

[73]  M. Grosso,et al.  Association of low‐risk MSH3 and MSH2 variant alleles with Lynch syndrome: Probability of synergistic effects , 2011, International journal of cancer.

[74]  D. Koh,et al.  Microsatellite instability and MLH1 hypermethylation – incidence and significance in colorectal polyps in young patients , 2007, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[75]  Ira M Lubin,et al.  A report template for molecular genetic tests designed to improve communication between the clinician and laboratory. , 2012, Genetic testing and molecular biomarkers.

[76]  S. Kakar,et al.  Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps , 2008, International journal of cancer.

[77]  R. White.  Colon cancer. Molecular biology of the APC protein. , 1997, Pathologie et biologie.

[78]  G. Deng,et al.  BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer , 2004, Clinical Cancer Research.

[79]  W. Grody,et al.  ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007 , 2008, Genetics in Medicine.

[80]  S. Gruber,et al.  Colorectal Polyps in Carriers of the APC I1307K Polymorphism , 2005, Diseases of the colon and rectum.

[81]  S. Thibodeau,et al.  MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. , 2004, Gastroenterology.

[82]  Siân Jones,et al.  Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C-->T:A mutations. , 2002, Human molecular genetics.

[83]  H. Hollema,et al.  Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome , 2009, Genes, chromosomes & cancer.

[84]  T. Venesio,et al.  High frequency of MYH gene mutations in a subset of patients with familial adenomatous polyposis. , 2004, Gastroenterology.

[85]  D. Provenzale,et al.  Using NCCN clinical practice guidelines in oncology to measure the quality of colorectal cancer care in the veterans health administration. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[86]  Jeffrey R. Botkin,et al.  Summary of Recommendations: The Evaluation of Genomic Applications , 2022 .

[87]  A. Spurdle,et al.  Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification , 2012, Journal of Medical Genetics.

[88]  M. Urioste,et al.  MLH1 germline epimutations in selected patients with early‐onset non‐polyposis colorectal cancer , 2007, Clinical genetics.

[89]  E. Hutchinson.  Alfred Knudson and his two-hit hypothesis , 2001 .

[90]  J. Stockman.  Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome , 2013 .

[91]  J. Peto,et al.  Prevalence of the APC E1317Q variant in colorectal cancer patients. , 2000, Cancer letters.

[92]  C. Adebamowo,et al.  Polymorphic variation at the BAT-25 and BAT-26 loci in individuals of African origin. Implications for microsatellite instability testing. , 1999, The American journal of pathology.

[93]  J. Lefèvre.  Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors , 2013 .

[94]  Shuji Ogino,et al.  Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. , 2006, The Journal of molecular diagnostics : JMD.

[95]  Ram Datar,et al.  DNA extraction from archival formalin-fixed, paraffin-embedded tissues: heat-induced retrieval in alkaline solution , 2004, Histochemistry and Cell Biology.

[96]  M. Trivett,et al.  Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer , 2007, Familial Cancer.

[97]  K. Søreide.  Molecular Testing for Microsatellite Instability and DNA Mismatch Repair Defects in Hereditary and Sporadic Colorectal Cancers – Ready for Prime Time? , 2007, Tumor Biology.

[98]  R. Go,et al.  Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  T. Eisen,et al.  Inherited variants in MYH are unlikely to contribute to the risk of lung carcinoma , 2003, Human Genetics.

[100]  D. Bercovich,et al.  Molecular analysis of the APC gene in 71 Israeli families: 17 novel mutations , 2002, Human mutation.

[101]  G. Deng,et al.  Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer , 2002, British Journal of Cancer.

[102]  J. Knight,et al.  Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. , 2004, Journal of the National Cancer Institute.

[103]  E. Bakker,et al.  Somatic APC mosaicism: an underestimated cause of polyposis coli , 2007, Gut.

[104]  G. Deng,et al.  [Analysis of the methylation in CpG island by denaturing high-performance liquid chromatography]. , 2001, Zhonghua yi xue za zhi.